Free Content Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma

Authors: Zhao, Fei; Obermann, Sonja1; von Wasielewski, Reinhard2; Haile, Lydia; Manns, Michael P.1; Korangy, Firouzeh; Greten, Tim F.

Source: Immunology, Volume 128, Number 1, September 2009 , pp. 141-149(9)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary

Pancreatic adenocarcinoma is one of the deadliest cancers with poor survival and limited treatment options. Immunotherapy is an attractive option for this cancer that needs to be further developed. Tumours have evolved a variety of mechanisms to suppress host immune responses. Understanding these responses is central in developing immunotherapy protocols. The aim of this study was to investigate potential immune suppressor mechanisms that might occur during development of pancreatic tumours. Myeloid-derived suppressor cells (MDSC) from mice with spontaneous pancreatic tumours, mice with premalignant lesions as well as wild-type mice were analysed. An increase in the frequency of MDSC early in tumour development was detected in lymph nodes, blood and pancreas of mice with premalignant lesions and increased further upon tumour progression. The MDSC from mice with pancreatic tumours have arginase activity and suppress T-cell responses, which represent the hallmark functions of these cells. Our study suggests that immune suppressor mechanisms generated by tumours exist as early as premalignant lesions and increase with tumour progression. These results highlight the importance of blocking these suppressor mechanisms early in the disease in developing immunotherapy protocols.

Keywords: immune suppressor mechanisms; immunotherapy; myeloid-derived suppressor cell; T cell; tumour immunology

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2567.2009.03105.x

Affiliations: 1: Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover 2: MVZ wagnerstibbe für Laboratoriumsmedizin, Gynäkologie, Humangenetik und Pathologie, Bad Münder, Germany

Publication date: 2009-09-01

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page